Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy.
Oxprenolol is a nonselective beta-adrenergic blocking agent that also possesses intrinsic sympathomimetic activity (ISA) and membrane stabilizing effects. Oxprenolol undergoes first pass metabolism with only 30% of an oral dose reaching the systemic circulation. The drug is approximately 80% protein bound and is eliminated primarily by glucuronidation in the liver. Less than 4% of oxprenolol is excreted unchanged in the urine. Oxprenolol may reduce the heart rate and prolong the effective and functional atrioventricular nodal refractory period. Oxprenolol has less negative inotropic and chronotropic effects than propranolol. Plasma renin activity is reduced; however, changes in plasma aldosterone level are not significant. Long term metabolic effects require further study. Oxprenolol appears to be comparable to other beta blockers in the treatment of hypertension and angina pectoris with no additional adverse reactions. If its partial agonist effect proves useful, it may have an advantage over other agents in treating patients with borderline cardiac reserve. Because of limited data, the use of oxprenolol for the treatment of arrhythmias, migraine, thyrotoxicosis, anxiety, and glaucoma cannot be recommended at this time.
D000403:Airway Resistance / Q000187:drug effects; D000787:Angina Pectoris / Q000188:drug therapy; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002462:Cell Membrane / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007700:Kinetics; D008074:Lipoproteins / Q000378:metabolism; D010096:Oxprenolol / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D012083:Renin / Q000097:blood; D013566:Sympathomimetics / Q000494:pharmacology
D008074:Lipoproteins; D013566:Sympathomimetics; D010096:Oxprenolol; D012083:Renin